Table 2 |
|||||||
|
General presentation of the 12 patients with 'complete lupus' |
|||||||
|
Patient |
Before anti-TNF alpha treatment |
During onset of symptoms |
|||||
|
|
|||||||
|
Disease |
Autoantibody |
Clinical signs of lupus |
Treatment |
Duration of treatment (months) |
Clinical signs of lupusa |
Biological signs of lupus |
|
|
|
|||||||
|
1 |
RA, RF+, erosive |
None |
None |
INF |
27 |
General, skin, serositis, lung |
ANA+, dsDNA+, ACL+, leucopenia, thrombopenia, ENA+ |
|
2 |
RA, RF+, erosive |
ANA+, Ro+ |
None |
INF |
4 |
General, skin (3), arthritis |
ANA+, dsDNA+, histone + |
|
3 |
RA, RF+, erosive |
ANA+, Ro+ |
None |
INF |
2 |
Skin, myalgias, arthritis |
ANA+, dsDNA+, ENA+, |
|
4 |
RA, RF-, erosive |
None |
None |
ETA |
4 |
General, skin (2), myositis |
ANA+, dsDNA+, ACL+, low C4, ENA+ |
|
5 |
RA, RF+, erosive |
None |
None |
INF |
4 |
Skin (3), myositis, arthritis, pericarditis |
ANA+, dsDNA+, ACL+, CPK, lymphopenia |
|
6 |
RA, RF+, erosive |
ANA+, dsDNA+ limit value |
None |
ETA |
5 |
General, skin |
ANA+, dsDNA+, thrombopenia, leucopenia |
|
7 |
RA, RF+, erosive |
None |
None |
INF |
10 |
General, serositis, myositis |
ANA+, dsDNA+, ACL+, leucopenia, thrombopenia, CPK, |
|
8 |
RA, RF+ |
None |
None |
ETA |
2 |
Phlebitis, skin |
ANA+, dsDNA+, leucopenia, ACL+, thrombopenia |
|
9 |
Psoriatic arthritis |
None |
None |
INF |
14 |
General, skin, neurological |
ANA+, dsDNA+ |
|
10 |
RA, RF+, erosive |
None |
None |
INF |
16 |
General, Skin, arthritis |
ANA+, dsDNA+ |
|
11 |
RA, RF+, erosive |
None |
None |
INF |
12 |
General, skin (3), arthritis, myositis |
ANA+, dsDNA+, ENA+, CPK |
|
12 |
RA, RF+, erosive |
None |
None |
INF |
10 |
General, skin, arthritis |
ANA+, dsDNA+, CPK, ENA+, ACL+, low C4, histone+, leucopenia, lymphopenia, Coombs test+ |
|
|
|||||||
|
ACL, positive anticardiolipin antibodies; ANA, antinuclear antibodies; CPK, creatin phospokinase or muscle enyme, elevated muscle enzymes; dsDNA, double-strand DNA; ENA, positive anti-extractable nuclear antigens antibodies; ETA, etanercept; general, general manifestations (fever, weight loss, asthenia); histone, positive anti-histone antibodies; INF, infliximab; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor; +, positive; -, negative. aThe skin manifestations were as follows (number in parentheses indicates number of skin manifestations observed in one patient): maculo papular rash observed in six patients, butterfly rash observed in five patients, alopecia present in one patient, photosensitivity observed in five patients, purpuric lesions observed in two patients. One patient had no skin manifestations, seven patients had one sign, one patient had two different signs, and three patients had three skin manifestations. |
|||||||
|
De Bandt et al. Arthritis Research & Therapy 2005 7:R545 doi:10.1186/ar1715 |
|||||||